ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
Whitney Gibb used to move through life at full speed. After COVID, brain fog, fatigue, and memory loss reshaped her daily life — offering a powerful window into the realities of Long COVID and the research now working to understand it.
Scientists at the Institute for Systems Biology (ISB) reveal how T cells “decide” their fate in fighting infections like COVID-19, paving the way for improved treatments for infections, cancer, and autoimmune diseases.
Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.